Syndax Pharmaceuticals (SNDX) Tops Q4 EPS by 3c

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q4 EPS of ($0.62), $0.03 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $0 versus the consensus estimate of $1.6 million.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
• Gemini Space Station, Inc. (GEMI) Misses Q2 EPS by 32c